TY - JOUR
T1 - Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)
AU - Baldelli, Roberto
AU - Colao, Annamaria
AU - Razzore, Paola
AU - Jaffrain-Rea, Marie Lise
AU - Marzullo, Paolo
AU - Ciccarelli, Enrica
AU - Ferretti, Elisabetta
AU - Ferone, Diego
AU - Gaia, Daniela
AU - Camanni, Franco
AU - Lombardi, Gaetano
AU - Tamburrano, Guido
PY - 2000
Y1 - 2000
N2 - Pharmacotherapy of acromegaly has been improved in recent years as new long-acting somatostatin analogs have became available; they have been suggested as an alternative treatment to pituitary surgery and radiotherapy. To avoid the inconvenience of multiple daily injections during long-term therapy, a slow release formulation of lanreotide (LAN), to be administered im at a dose of 30 mg every 7-14 days, has been introduced in the therapeutic management. The suppressive effects of a short-term LAN treatment on GH and insulin-like growth factor I (IGF-I) hypersecretion were shown to be similar to those obtained with sc octreotide. However, scant data have been reported concerning a long-term treatment with this drug. In the present study the efficacy and tolerability of a 24-month LAN treatment were evaluated in 118 active acromegalic patients; 71 had been previously operated on and treated with sc octreotide (operated patients), 24 previously operated on had been irradiated and treated with sc octreotide (irradiated patients), and the remaining 23 were newly diagnosed (de novo patients). The efficacy was considered on the basis of controlled GH (fasting,
AB - Pharmacotherapy of acromegaly has been improved in recent years as new long-acting somatostatin analogs have became available; they have been suggested as an alternative treatment to pituitary surgery and radiotherapy. To avoid the inconvenience of multiple daily injections during long-term therapy, a slow release formulation of lanreotide (LAN), to be administered im at a dose of 30 mg every 7-14 days, has been introduced in the therapeutic management. The suppressive effects of a short-term LAN treatment on GH and insulin-like growth factor I (IGF-I) hypersecretion were shown to be similar to those obtained with sc octreotide. However, scant data have been reported concerning a long-term treatment with this drug. In the present study the efficacy and tolerability of a 24-month LAN treatment were evaluated in 118 active acromegalic patients; 71 had been previously operated on and treated with sc octreotide (operated patients), 24 previously operated on had been irradiated and treated with sc octreotide (irradiated patients), and the remaining 23 were newly diagnosed (de novo patients). The efficacy was considered on the basis of controlled GH (fasting,
UR - http://www.scopus.com/inward/record.url?scp=17744366379&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17744366379&partnerID=8YFLogxK
U2 - 10.1210/jc.85.11.4099
DO - 10.1210/jc.85.11.4099
M3 - Article
C2 - 11095439
AN - SCOPUS:17744366379
VL - 85
SP - 4099
EP - 4103
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 11
ER -